18F-flortaucipir and 18F-THK5351 studies found the strongest binding differences for the globus pallidus, the subthalamic nucleus, and the midbrain when comparing individuals with PSP with healthy controls.7,8,24,25 However, large proportions of the basal ganglia signal of 18F-THK5351 in individuals with PSP and healthy controls were not specific for tau.26 We observed only minor elevation above a DVR of 1.0 in healthy controls for 18F-PI-2620 in all brain regions apart from the substantia nigra, suggesting low off-target binding for 18F-PI-2620 in PSP target regions. This evidence concerns the gene MAPT and supranuclear palsy, progressive, 1.